Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.46 |
| ▸ | FPR2 | P25090 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979601 | 0.91 | SCN9A (0.46) | SCN9AFPR2SYKPIK3CAKDM4E | |
| SCHEMBL1980493 | 0.83 | XIAP (0.46) | MAPTKDM4EALDH1A1RECQLLTA4H | |
| SCHEMBL1979735 | 0.81 | KEAP1 (0.42) | SCN9AFPR2MAPTSYKPIK3CA | |
| SCHEMBL17350062 | 0.81 | KMT2A (0.45) | MAPTKDM4EALDH1A1RECQLGRM4 | |
| SCHEMBL12594162 | 0.79 | MAPT (0.43) | MAPTKDM4EALDH1A1RECQLLTA4H | |
| SCHEMBL1981054 | 0.79 | FPR2 (0.46) | SCN9AFPR2MAPTSYKKDM4E | |
| SCHEMBL1978742 | 0.78 | AAK1 (0.48) | MAPTKDM4EALDH1A1RECQLLTA4H | |
| SCHEMBL20906310 | 0.78 | AAK1 (0.48) | MAPTKDM4EALDH1A1RECQLLTA4H | |
| SCHEMBL1983127 | 0.78 | AAK1 (0.48) | MAPTKDM4EALDH1A1RECQLLTA4H | |
| SCHEMBL20567337 | 0.78 | SCN9A (0.44) | SCN9AFPR2SYKLTA4HGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170065585-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| EP-2509961-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-20170065585-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | SCN9A 88/4885FPR2 4838/4885MAPT 3762/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 93/4885FPR2 4820/4885MAPT 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.